AT1 RECEPTOR AUTOANTIBODIES MEDIATE EFFECTS OF METABOLIC SYNDROME ON DOPAMINERGIC VULNERABILITY.

• Ana Isabel Rodríguez Pérez,
• María A Pedrosa,
• Carmen M Labandeira,
• Rita Valenzuela,
• Aloia Quijano,
• Mariña Sanchez-Andrade,
• Juan Antonio Suárez-Quintanilla,
• Jose Lanciego,
• José Luis Labandeira-García

Affiliations

Ana Isabel Rodríguez Pérez

Research Center for Molecular Medicine and Chronic diseases (CIMUS), Idis, University Of Santiago De Compostela, Santiago de Compostela, Spain; Networking Research Center on Neurodegenerative Diseases, Ciberned, Madrid, Spain

María A Pedrosa

Research Center for Molecular Medicine and Chronic diseases (CIMUS), Idis, University Of Santiago De Compostela, Santiago de Compostela, Spain; Networking Research Center on Neurodegenerative Diseases, Ciberned, Madrid, Spain

Carmen M Labandeira

Research Center for Molecular Medicine and Chronic diseases (CIMUS), Idis, University Of Santiago De Compostela, Santiago de Compostela, Spain; University Hospital of Ourense, Clinical Neurology, Ourense, Spain; Hospital Alvaro Cunqueiro, University Hospital Complex, Clinical Neurology, Vigo, Spain

Rita Valenzuela

Research Center for Molecular Medicine and Chronic diseases (CIMUS), Idis, University Of Santiago De Compostela, Santiago de Compostela, Spain; Networking Research Center on Neurodegenerative Diseases, Ciberned, Madrid, Spain

Aloia Quijano

Research Center for Molecular Medicine and Chronic diseases (CIMUS), Idis, University Of Santiago De Compostela, Santiago de Compostela, Spain

Mariña Sanchez-Andrade

University Clinical Hospital of Santiago de Compostela, Obstetric Service, Santiago de Compostela, Spain

Juan Antonio Suárez-Quintanilla

Primary Health-Care Unit Fontiñas, Idis, Santiago de Compostela, Spain

Jose Lanciego

Networking Research Center on Neurodegenerative Diseases, Ciberned, Madrid, Spain; Centro de Investigación Médica Aplicada, Cns Gene Therapy Program, Pamplona, Spain; Aligning Science Across Parkinson's Collaborative Research Network, Asap, Chevy Chase, United States of America

José Luis Labandeira-García

Research Center for Molecular Medicine and Chronic diseases (CIMUS), Idis, University Of Santiago De Compostela, Santiago de Compostela, Spain; Networking Research Center on Neurodegenerative Diseases, Ciberned, Madrid, Spain